{
    "eid": "2-s2.0-85081200562",
    "title": "Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: A multicentre cohort study",
    "cover-date": "2020-03-05",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Gastroenterology",
            "@code": "2715",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Daclatasvir",
        "Effectiveness",
        "Hepatitis C",
        "Safety",
        "Sofosbuvir",
        "Velpatasvir"
    ],
    "authors": [
        "Phunchai Charatcharoenwitthaya",
        "Virasak Wongpaitoon",
        "Piyawat Komolmit",
        "Wattana Sukeepaisarnjaroen",
        "Pisit Tangkijvanich",
        "Teerha Piratvisuth",
        "Theeranun Sanpajit",
        "Chinnavat Sutthivana",
        "Chalermrat Bunchorntavakul",
        "Abhasnee Sobhonslidsuk",
        "Soonthorn Chonprasertsuk",
        "Chotipong Siripipattanamongkol",
        "Supatsri Sethasine",
        "Tawesak Tanwandee"
    ],
    "citedby-count": 17,
    "ref-count": 44,
    "ref-list": [
        "Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study",
        "A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C",
        "Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis",
        "Electronic address eee, European Association for the Study of the L: EASL recommendations on treatment of hepatitis C 2018",
        "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection",
        "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection",
        "Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis",
        "Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection",
        "All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study",
        "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)",
        "Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection",
        "Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection",
        "Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis",
        "Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/ritonavir/Ombitasvir and Dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs National Health Care System",
        "Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort",
        "Effectiveness of Ledipasvir-Sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained Virologic response",
        "Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort",
        "Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients",
        "The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease",
        "Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: Real-world results from 18 378 patients in Egypt",
        "Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)",
        "Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3",
        "Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection",
        "Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data",
        "Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: Real-world experience in Vietnam",
        "High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in Myanmar",
        "Direct-acting antivirals in east Asian hepatitis C patients: Real-world experience from the REAL-C consortium",
        "A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt",
        "A new equation to estimate glomerular filtration rate",
        "Kidney disease: Improving global outcomes chronic kidney disease guideline development work group M: Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline",
        "Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: A single-arm, open-label, phase 3 trial",
        "Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4",
        "Open label study of 8 vs. 12 weeks of Ledipasvir/Sofosbuvir in genotype 6 treatment naive or experienced patients",
        "Ledipasvir and Sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease",
        "Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial",
        "Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis",
        "Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry",
        "Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study",
        "Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation",
        "Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection",
        "Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study",
        "Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list",
        "The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities",
        "Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: A meta-analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": null,
            "@id": "60022738",
            "affilname": "Bhumibol Adulyadej Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022738",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60020543",
            "affilname": "Bumrungrad International Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020543",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60020352",
            "affilname": "Vajira Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020352",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60017165",
            "affilname": "Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017165",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60012521",
            "affilname": "Thammasat University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012521",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60006964",
            "affilname": "Phramongkutklao College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006964",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60005255",
            "affilname": "Rajavithi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005255",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chiangmai",
            "@id": "101348625",
            "affilname": "Chiangrai Prachanukroh Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101348625",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}